Phaseline

Targets › ARNT

ARNT (Aryl hydrocarbon receptor nuclear translocator): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Transcription factor that functions as an obligate heterodimerization partner for several basic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) proteins. Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target gene promoters. (UniProt, P27540)

Open in Phaseline: the race on ARNT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NeomorphNEO-811
ARNT molecular glue degrader
ARNTPhase 1Clear Cell Renal Cell CarcinomaJan 2027

Conditions

Clear Cell Renal Cell Carcinoma (1)

Modalities

small molecule (1)

Companies

Neomorph (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.